Insider Transactions in Q1 2026 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 13
2026
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
2,290
-1.69%
|
$847,300
$370.8 P/Share
|
|
Jan 12
2026
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,510
-0.3%
|
$549,640
$364.8 P/Share
|
|
Jan 12
2026
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,510
-0.24%
|
$549,640
$364.8 P/Share
|
|
Jan 12
2026
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,780
-0.22%
|
$1,011,920
$364.8 P/Share
|
|
Jan 12
2026
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,577
-0.55%
|
$3,486,028
$364.8 P/Share
|
|
Jan 12
2026
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
1,510
-0.31%
|
$549,640
$364.8 P/Share
|
|
Jan 11
2026
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,800
+13.17%
|
-
|
|
Jan 11
2026
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,800
+10.85%
|
-
|
|
Jan 11
2026
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,193
+9.32%
|
-
|
|
Jan 11
2026
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,003
+17.76%
|
-
|
|
Jan 11
2026
|
Pushkal Garg EVP Chief R&D |
BUY
Grant, award, or other acquisition
|
Direct |
3,800
+13.66%
|
-
|